Clonal hematopoiesis of indeterminate potential (CHIP) occurs in the blood of approximately 20% of older persons. CHIP is linked to an increased risk of hematologic malignancies and of all-cause mortality; thus, the eligibility of stem-cell donors with CHIP is questionable. We comprehensively investigated how donor CHIP affects outcome of allogeneic hematopoietic stem-cell transplantation (HSCT).
Clonal hematopoiesis of indeterminate potential (CHIP) occurs in the blood of approximately 20% of older persons. CHIP is linked to an increased risk of hematologic malignancies and of all-cause mortality; thus, the eligibility of stem-cell donors with CHIP is questionable. We comprehensively investigated how donor CHIP affects outcome of allogeneic hematopoietic stem-cell transplantation (HSCT).
Methods
We collected blood samples from 500 healthy, related HSCT donors (age $ 55 years) at the time of stem-cell donation for targeted sequencing with a 66-gene panel. The effect of donor CHIP was assessed on recipient outcomes, including graft-versus-host disease (GVHD), cumulative incidence of relapse/progression (CIR/P), and overall survival (OS).
Results
A total of 92 clonal mutations with a median variant allele frequency of 5.9% were identified in 80 (16.0%) of 500 donors. CHIP prevalence was higher in donors related to patients with myeloid compared with lymphoid malignancies (19.2% v 6.3%; P # .001). In recipients allografted with donor CHIP, we found a high cumulative incidence of chronic GVHD (cGVHD; hazard ratio [HR], 1.73; 95% CI, 1.21 to 2.49; P = .003) and lower CIR/P (univariate: HR, 0.62; 95% CI, 0.40 to 0.97; P = .027; multivariate: HR, 0.63; 95% CI, 0.41 to 0.98; P = .042) but no effect on nonrelapse mortality. Serial quantification of 25 mutations showed engraftment of 24 of 25 clones and disproportionate expansion in half of them. Donor-cell leukemia was observed in two recipients. OS was not affected by donor CHIP status (HR, 0.88; 95% CI, 0.65 to 1.321; P = .434).
INTRODUCTION
Clonal hematopoiesis, defined by the presence of a somatic hematologic cancer-associated gene mutation, occurs in the peripheral blood of at least 10% of people older than 60 years of age without any history of hematologic disorder. [1] [2] [3] Mutation frequencies increase in an age-related manner and mainly affect epigenetic regulators of transcription (ASXL1, DNMT3A, and TET2). To distinguish clonal hematopoiesis from idiopathic and clonal cytopenias of undetermined significance, a new definition, termed clonal hematopoiesis of indeterminate potential (CHIP), has been proposed. 4 CHIP is defined by the absence of definitive morphologic evidence of hematologic neoplasms and the presence of a somatic mutation with a variant allele frequency (VAF) of at least 2%. CHIP is associated with an increased risk of hematologic cancers, cardiovascular disease, and death from coronary heart disease, which collectively lead to an increased overall mortality. 5 CHIP derives most likely from mutated Lin 2 CD34 + CD38
2 hematopoietic stem cells (HSCs) 6 and may precede many hematologic disorders. [7] [8] [9] [10] [11] [12] However, in the vast majority of healthy individuals, mutated HSCs have been shown to be stable over many years without causing disease signs, so individual predictions of the malignant transformation potential are highly challenging. 13 To date, little is known about the influence of donor CHIP in the setting of allogeneic HSC transplantation (HSCT). Case reports indicate that pre-existing donor CHIP may lead to donor-cell leukemia (DCL).
14-16 DCL represents a relatively rare complication that affects 0.1% of those who undergo transplantion. 17, 18 In addition, it has been shown that five of six recipients with unexplained cytopenias received allografts from donors with DNMT3A mutation. 19 Nonmalignant outcome consequences of donor CHIP, such as graft function and/or immunologic impairment, may be more common than DCL and may thereby contribute to HSCT outcome.
The number of older patients who undergo allogeneic HSCT is constantly increasing because of reduced-intensity conditioning regimens. Currently, approximately one fifth of patients who undergo allogeneic HSCT are $ 60 years of age. 20 The increasing number of older allogeneic HSCT recipients is paralleled by a continuous increase in older donors, mostly siblings of older patients in need of allogeneic HSCT. Therefore, it is of utmost importance to investigate how donor CHIP affects transplantation outcomes, including GVHD development, relapse, and overall survival (OS), and to determine the extent that donor CHIP should be considered during donor selection.
In this study, we investigated CHIP in 500 related HSCT donors age $ 55 years and systematically delineated the clinical effect of CHIP in allogeneic HSCT. Furthermore, we tracked the dynamic evolution of 25 donor mutations in 22 patients who underwent CHIP transplantations and studied one DCL occurrence by wholeexome sequencing (WES). Collectively, our data pinpoint a previously unknown and important influence of CHIP in HSCT.
METHODS

Study Design and Participants
We designed a retrospective, multicenter study to investigate the prevalence of CHIP among older donors and its effects on HSCT. Healthy donors $ 55 years of age were included if a peripheral-blood or bone marrow sample before or at the time of donation was available and if sufficient demographic and clinical data were present for both donor and recipient in an anonymized fashion. This study focused on related donors, because these represent the main source of older HSCT donors. In total, 500 donor-recipient couples were included from 10 transplantation centers in Germany and France (Data Supplement). The study was conducted in accordance with the Declaration of Helsinki, and ethical approval was obtained from the local ethics committees.
Procedures
Samples were collected between 1993 and 2017. Whole-blood DNA was screened for CHIP using two customized versions of the TruSight Myeloid Sequencing Panel (Illumina, San Diego, CA), customized version I (n = 345), and customized version II (n = 155; Data Supplement) according to the manufacturer's protocol. Libraries were paired-end sequenced on a MiSeq or NextSeq sequencer. Targeted deep sequencing (TDS) and sequencing data analysis were performed as previously described, 6, 9, [21] [22] [23] [24] and analysis is detailed in the Data Supplement. WES was performed in one DCL case using paired whole-blood DNA from time of donation and time of DCL diagnosis, as previously described.
23,25,26
Statistical Analysis
Primary analysis was performed on OS, defined as the time since transplantation until death as a result of any cause. The Kaplan-Meier method and log-rank tests were used to estimate the distribution of OS and to compare differences between survival curves. Median follow-up was calculated using the reverse Kaplan-Meier method. Sensitivity analyses were performed for nonrelapse mortality (NRM) and cumulative incidence of relapse/progression (CIR/P). Acute and chronic graft-versushost disease (aGVHD and cGVHD, respectively) were clinically and histologically diagnosed by treating physicians and graded per Glucksberg classification or National Institutes of Health consensus criteria, respectively.
27,28 NRM was defined as death without relapse/progression. CIR/P was defined as relapse/progression from underlying hematologic malignancy. Disease remission status was evaluated directly before transplantation. Competing risk analyses for leukocyte and thrombocyte engraftment, aGVHD, cGVHD, cytomegalovirus (CMV) reactivation, NRM, and CIR/P were performed using Gray's test (respective competing risk factors are listed in the Data Supplement). Cumulative incidences between groups were assessed and visualized using Gray's test, and estimates were reported with 95% CIs using the method of Fine and Gray. Baseline parameters (Data Supplement) with unadjusted univariate P values of # .1 were selected for multivariate analyses using the method of Fine and Gray. Time to cGVHD development used a Fine and Gray competing risks regression model and was adjusted for donor age, antithymocyte globulin (ATG) application, and CHIP/DNMT3A mutation status. Time to relapse/ progression used a Fine and Gray competing risks regression model and was adjusted for disease type, conditioning regimen intensity, ATG application, and CHIP/DNMT3A mutation status. Pairwise comparisons of variables for exploratory purposes were performed using Mann-Whitney, x 2 , or Fisher's exact tests. The two-sided level of significance was set at a P value of , .05 without adjustment for multiple testing. The statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS) for Windows version 23.0 (IBM Corporation, Armonk, NY) and statistical program R version 3.3.1 with packages "survival," "cmprsk," and "forestplot."
RESULTS
Mutation Analysis of CHIP in Older HSCT Donors
Sequencing screening (mean coverage, 2,033 reads/amplicon/ sample were obtained) and subsequent validation identified 92 clonal mutations in 80 (16.0%) of 500 older donors (Data Supplement). The median VAF was 5.9% (range, 2% to 43%), and 25 variants in 20 patients were present at a VAF of 10% or greater. In 70 donors, one single gene mutation could be detected, whereas nine donors showed two mutations, and one donor had four mutations. The most frequently mutated genes were DNMT3A (40 of 500; 8%), TET2 (11 of 500; 2.2%), and ASXL1 (seven of 500; 1.4%; Fig 1) . Among the 10 donors with more than one mutation, the most frequent combination was DNMT3A/DNMT3A (n = 4) followed by DNMT3A/ASXL1 (n = 3). Among the 61 single nucleotide variants, 65.6% were transitions, with the most frequently occurring cytosine to thymine substitution representing a signature characteristic of aging (Data Supplement). 29 For DNMT3A, 44 variants were identified in 40 patients (Data Supplement).
Donors with or without CHIP did not differ in baseline characteristics, such as age, sex, or in the amount of harvested CD34 + HSCs per kilogram body weight of recipient. Likewise, donor CHIP status was evenly distributed with regard to demographic, disease, and transplantation characteristics of the recipient (Table 1 ; Data Supplement). Donor CHIP was present significantly more often in donors for recipients with myeloid than with lymphoid neoplasms (19.2% v 6.3%; P # .001; Table 1 ; Data Supplement).
Donor CHIP prevalence increased in an age-dependent manner from 10.3% among donors age 60 to 64 years to 20.3% (65 to 69 years), 22.5% (70 to 74 years), and 28.6% (75 to 79 years). However, no statistically significant association between CHIP and age could be observed, likely because 82% of all donors in our cohort were age 60 to 69 years.
Donor CHIP and Transplantation Outcome
Clinical data available about transplantation outcome parameters included time to engraftment, occurrence of aGVHD, cGVHD, CMV reactivation, DCL, and relapse/progression after HSCT (Data Supplement). Although donor CHIP did not have an effect on thrombocyte engraftment time, its presence led to a slightly faster leukocyte engraftment (cumulative incidence of engraftment after 15 days, 64.1% v 51.4%; P = .023). Cumulative incidence of cGVHD was higher after HSCT with donor CHIP (5-year cumulative incidence, 52.9% v 35.7%; P = .008). In multivariate analysis, donor CHIP was an independent risk factor for cGVHD development when analysis was adjusted for ATG application and donor age (hazard ratio, 1.73; 95% CI, 1.21 to 2.49; P = .003; Figs 2A and 2D).
To further delineate the association between donor CHIP and cGVHD, we investigated individual gene mutations and CHIP characteristics. The presence of a donor DNMT3A mutation could be identified as the predominant CHIP factor for cGVHD development in univariate (58.5% v 36.6%; P = .006; Figs 2B and 2C; Data Supplement) and multivariate (HR, 1.99; 95% CI, 1.28 to 3.12; P = .002; Data Supplement) analyses. Other CHIP mutations or characteristics had no effect on cGVHD development ( Fig 2C) .
Next, competing risk analysis for CIR/P and NRM were performed. At 5 years, CIR/P was 40% and NRM was 24.8%. Recipients who underwent HSCT with donor CHIP showed a decreased CIR/P (P = .027; Fig 3A) . Similarly, allogeneic HSCT from a donor with DNMT3A mutation was associated with a lower CIR/P (P = .029; Fig 3B) . No significant effect could be observed for NRM in either setting (Figs 3A and 3B). Donor-cell malignancies were observed in two recipients who underwent HSCT with donor CHIP (two of 82 recipients) but not in recipients who underwent HSCT from donors without CHIP (zero of 426 recipients; P = .026 by Fisher's exact test); these results demonstrated the expected elevated risk for DCL, as shown for unselected cohorts and patients with cancer and CHIP who are at increased risk of developing therapy-related myeloid neoplasms. 2, 3, 30, 31 Next, we performed separate competing risk analyses for patients who underwent transplantation in complete remission (CR) and for patients who were not in complete remission (in non-CR). In patients who underwent HSCT in CR (n = 192), neither donor CHIP nor a donor DNMT3A mutation affected CIR/P or NRM (Fig 3D; Data Supplement) . In contrast, patients who underwent HSCT in non-CR had a lower CIR/P when the donor was CHIP positive or had a DNMT3A mutation (CHIP: HR, 0.49; 95% CI, 0.27 to 0.88; P = .019; DNMT3A mutation: HR, 0.34; 95% CI, 0.15 to 0.81; P = .015; Fig 3D) . Again, no effect could be observed for NRM (Data Supplement). To identify possible confounders, we performed a multivariate analysis according to the method of Fine and Gray. Here, donor CHIP was identified as an independent factor for lower CIR/P (HR, 0.633; 95% CI, 0.41 to 0.98; P = .042; Fig 3C) , whereas acute myeloid leukemia (AML) was the only parameter associated with an increased CIR/P (HR, 1.33; 95% CI, 1.01 to 1.74; P = .043). Multivariate analysis in patients who underwent transplantation from donors with DNMT3A mutation showed that the presence of a donor DNMT3A mutation was significantly associated with a decreased CIR/P (HR, 0.494; 95% CI, 0.26 to 0.93; P = .029; Data Supplement).
In the subgroup of patients who underwent transplantation in non-CR (n = 303), multivariate analysis confirmed donor CHIP as an independent predictor for reduced CIR/P (HR, 0.46; 95% CI, Gene jco.org 0.25 to 0.88; P = .019; Data Supplement). As was shown for the entire cohort, allogeneic HSCT from a donor with DNMT3A-mutation was likewise associated with a lower CIR/P in recipients who underwent transplantation in non-CR (HR, 0.29; 95% CI, 0.12 to 0.74; P = .01; Data Supplement).
For patients alive, the median follow-up time was 3.3 years (range, 0.1 to 20.6 years). The median OS was 2 years, and the 5-year OS rate was 37.6%. Follow-up times did not differ between patients who underwent transplantation from donors with or without CHIP. Kaplan-Meier survival analyses did not show survival differences according to donor CHIP status (HR, 0.88; 95% CI, 0.65 to 1.321; P = 0.434; Fig 4A) . The same was true for patients who underwent HSCT from a donor with DNMT3A mutation (HR, 0.89; 95% CI, 0.58 to 1.35; P = .573; Fig 4B) . Of note, patients with myelodysplastic syndrome (MDS) and AML who underwent transplantation in non-CR (n = 152) had a survival benefit when the donor harbored a CHIP mutation (HR, 0.49; 95% CI, 0.28 to 0.86; P = .011; Data Supplement). In contrast, the presence of donor CHIP showed a trend toward reduced survival in the subcohort of patients with myeloproliferative neoplasia (n = 58; P = .077; Data Supplement).
Clonal Dynamics of Donor CHIP in the Recipient
To gain insights into the clonal dynamics of donor CHIP, we determined the VAF of CHIP clones in serial follow-up samples. Using TDS, a mean coverage of 51,278 reads/amplicon was achieved, which allowed reliable detection of low-burden mutations. Clonal dynamics were analyzed in the context of chimerism data to guarantee the most precise analysis possible. In 22 recipients, clonal donor mutations were analyzed with an average of five time points per patient (Fig 5; Data Supplement) . Pretransplantation recipient samples were available in 20 of 22 patients, in whom the presence of the respective donor mutation before transplantation could be excluded. According to their VAF dynamics, we assigned each mutation into "no engraftment," "linear expansion," or "disproportionate expansion" patterns. The disproportionate expansion pattern was used when a clone constantly doubled its allelic ratio over time. With the exception of an SF3B1 K700E-harboring clone (041R), all other CHIP clones engrafted in the recipients. To investigate the cellular origin and its repartition within the hematopoietic differentiation of this particular SF3B1 mutation, a total of 10 stem/progenitor and mature cell fractions were flow-sorted and quantified for the SF3B1 K700E allelic ratio by TDS. 6 The mutation occurred in Lin
HSCs at a VAF of 4.3% and subsequently expanded with a myeloid bias to reach the highest VAF of 9.3% in monocytes (Data Supplement). These data prove the stem-cell origin of the K700E mutation and suggest clonal disadvantage and/or negative selection, which explain engraftment failure of the mutated clone. Linear and disproportional engraftment patterns were observed in 10 and 11 recipients, respectively. In all but one recipient (443R) who had a disproportional expansion of the CHIP clone, no clinical sign of relapse and a 100% donor chimerism profile were noted. As prime example, in 457R, a DNMT3A mutation increased from 18% to 40% and remained at this high VAF during a followup time of more than 10 years. However, half of all recipients with a linear expansion profile experienced a relapse of the underlying disease. In all patients who experienced relapse, dynamics of the CHIP clones paralleled the decrease of donor chimerism. Finally, we studied both occurrences of DCL. The first patient had 100% chimerism and a donor CBLC mutation with a VAF of 8%, which rapidly increased to 37% and remained stable at this high VAF until diagnosis of DCL 550 days after allogeneic HSCT. Panel sequencing of the DCL sample revealed evidence of clonal evolution within the recipient, as indicated by newly acquired TP53 R175H (VAF, 25.9%) and BCORL1 A971G (x-chromosomal adjusted VAF, 32.2%) mutations within the donor CHIP clone defined by the initial CBLC mutation. The second DCL occurrence was diagnosed as high-risk donor-cell MDS, which we investigated by WES. The initial CHIP clone was defined by the presence of an ASXL1 and a DNMT3A mutation and VAFs between 2% and 3%. Four years after HSCT, this clone acquired a total of nine somatic mutations, including a RUNX1 splice site alteration (Data Supplement).
DISCUSSION
In this study, clonal hematopoiesis was identified in 80 (16.0%) of 500 older HSCT donors. The mutation prevalence and spectrum are in line with previous deep sequencing reports that investigated healthy individuals not enriched for associated risk factors, such as cancer or atherosclerosis. 32, 33 CHIP has been shown to be rare in healthy individuals before the sixth decade of life. [1] [2] [3] 32 In addition, hematologic cancers are associated with an increased familial risk.
34,35 Therefore, we decided to focus on related older donors ($ 55 years) to ascertain a homogenous age and relationship profile within our study. Surprisingly, we observed a higher donor CHIP jco.org prevalence in related individuals from patients with a myeloid compared with a lymphoid malignancy (19.2% v 6.3%; P # .001). As the most common CHIP mutations DNMT3A, TET2, and ASXL1 are predominantly involved in the pathogenesis of myeloid neoplasms, [36] [37] [38] jco.org and JAK2 V617F mutation.
39 Also a familial aggregation of TET2 mutations has been documented recently in healthy individuals. 33 However, large cohorts are now required to dissect associations between specific CHIP mutations and constitutional risk loci to more deeply investigate the role of constitutional predisposition(s) and CHIP.
With respect to early HSCToutcome parameters, donor CHIP status did not influence incidences of aGVHD development or CMV reactivation. A recent single-center study showed an association between CHIP and unexplained cytopenias at day 100 after HSCT, which we could not investigate because of lack of uniform data annotation in our multicenter study. 19 For the first time, to our knowledge, we showed that donor CHIP and especially the presence of DNMT3A-mutated clones are associated with the development of cGVHD, using multivariate analyses. Although only in vivo experiments can decipher mechanisms about how CHIP might lead to GVHD development, several hypotheses are conceivable. Functional studies in mice showed that monocytes/ macrophages with deleted TET2 initiate chronic inflammation by upregulating the expression of several chemokines and cytokines (mainly interleukin [IL]-1b), which leads to increased secretion and activation of the NLRP3 inflammasome and thus contributes to the formation of atherosclerotic plaques in mice. 5, 40 Importantly, transplantation of TET2-deficient bone marrow at a subclonal ratio of 10% was sufficient to create a strong proinflammatory environment. This subclonal ratio is almost identical to the one seen in our cohort, which had a median CHIP VAF of 6% that corresponded to 12% of hematopoietic cells that harbored CHIP. Furthermore, the NLRP3 complex has been shown to play a crucial role as a regulator of GVHD manifestation by controlling pro-IL1b cleavage.
41 DNMT3A has been reported as an epigenetic regulator of T-cell differentiation and proinflammatory cytokines (eg, IL-13), which both represent important steps of the pathophysiology of cGVHD.
42-44 Although we did not find any difference with respect to cGVHD severity, we observed a higher incidence of ocular GVHD in recipients who underwent HSCT from CHIP donors (Data Supplement). Collectively, our data extend reported associations between CHIP and inflammatory diseases, suggesting that aberrant inflammatory responses are a central commonality among CHIP, aging-associated diseases, and GVHD. 45 Competing risk analysis identified donor CHIP as an independent factor for reduced incidence of relapse/progression. This effect was more pronounced in recipients who underwent HSCT in non-CR. Several explanations are conceivable. First, CHIP clones possess a competitive advantage and might better compete with residual malignant cells. In fact, more than half of the donors with CHIP showed somatic mutations in the epigenetic regulators DNMT3A and TET2. Mutations in both genes provide a competitive advantage to mutated HSCs through enhanced selfrenewal, which leads to HSC expansion and subsequent perturbed hematopoietic differentiation. 12, 46 Longitudinal tracking of mutated donor clones in the recipient supports the idea of such a competitive advantage. However, it has also been shown that differentiation blockade is not completely penetrant and that mutant HSCs produce mature, differentiated cells that contribute to homeostasis and host defense. 12, 46 Therefore, it is also conceivable that donor CHIP may alter immune responses that foster graft-versus-leukemia effects.
In a series of 400 patients with lymphoma who underwent autologous SCT, individuals with CHIP had significantly inferior OS compared with those without CHIP. 47 However, in allogeneic HSCT, the situation is different; donor CHIP clones have not been opposed to cytotoxic reagents and face different and likely stronger immunologic cellular stressors. To our knowledge, we showed, for the first time, that donor CHIP did not affect the survival of 500 HSCT recipients. Neither a single gene mutation, nor the clone size, nor the number of donor CHIP mutations was associated with any survival difference. In addition, the 5-year OS rate of 37% in our cohort was almost shortened by half compared with the autologous SCT lymphoma cohort, which leads to speculation that severe adverse effects of CHIP, such as atherosclerotic plaque formation, might occur after longer latency. Only in patients with myeloproliferative neoplasia was donor CHIP associated by trend with shorter OS (P = .077), but distribution of hematologic disorders that led to HSCT varied among this subgroup (Data Supplement). Although the reduction of CIR/P did not translate into prolonged OS in the entire cohort, and although causal reasons such as varied treatment strategies for relapse remain speculative, we observed longer OS with donor CHIP for patients with AML/MDS who underwent transplantation in non-CR. This finding could implicate an important clinical potential in this difficult-to-treat subgroup. HSCT from donor CHIP did not show elevated NRM, and no higher incidence of fatal cardiovascular events that led to death was noted (Data Supplement). However, prospective observation studies will be required to assess potential associations between donor CHIP and development of newly acquired, nonfatal diseases, such as heart failure or peripheral arterial disease, after allogeneic HSCT.
Allogeneic HSCT from a donor with CHIP appears safe and results in similar OS in the setting of older and related donors. Although there is a slightly increased risk for DCL in recipients who underwent HSCT from a CHIP-harboring donor, this does not affect overall outcome. Donor CHIP might in turn increase cGVHD rates that are associated with reduced relapse/progression risk. This study was conducted as an exploratory study. As a consequence, we did not restrict the number of tests for associations of CHIP with clinical outcomes. We acknowledge that owing to the multiple tests, the P values do not picture the global type I error. Future studies in younger and unrelated donors, as well as functional investigations, are now warranted to confirm these results and decipher molecular mechanisms.
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